Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biogen, Inc.
In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.
Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.
Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.
Management tried to sidestep controversy around the approval of Aduhelm and said it remains confident the drug will be reimbursed.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Biogen Idec
- Convergence Pharmaceuticals Ltd
- Nightstar Therapeutics plc
- Stromedix, Inc.
- Syntonix Pharmaceuticals